Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

ABSTRACT:

SUBMITTER: Valencia-Martinez A

PROVIDER: S-EPMC5685232 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Mutated <i>ASXL1</i> and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Valencia-Martinez Ana A Sanna Alessandro A Masala Erico E Contini Elisa E Brogi Alice A Gozzini Antonella A Santini Valeria V

Haematologica 20170518 9

PMID: 28522578

Similar Datasets

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Project description: Not available

| S-EPMC3809801 | biostudies-literature

Multilineage dysplasia and AML with mutated nucleophosmin

Project description:Multilineage dysplasia (MLD) has no impact on biological, clinico-pathological and prognostic features of AML with mutated nucleophosmin (NPM1) NPM1-mutated AML is a provisional entity in the WHO-2008 classification of myeloid neoplasms. The significance of concomitant multilineage dysplasia (MLD) in NPM1-mutated AML is unclear. Thus, in the WHO-2008 classification, NPM1-mutated AML with MLD is classified as AML with myelodysplasia(MD)-related changes. We evaluated the MLD impact in 378 NPM1-mutated AML patients. MLD was found in about 25% cases. Except for a lower WBC and FLT3-ITD incidence in MLD+ group, no significant differences were observed in age, sex, cytogenetics and FLT3-TKD between NPM1-mutated AML with and without MLD. Notably, NPM1-mutated AML with/without MLD showed overlapping immunophenotype (CD34-negativity) and GEP (CD34 downregulation and HOX genes upregulation). Moreover, OS and EFS did not differ among NPM1-mutated AML patients, independently of whether they carried or not MLD, the NPM1-mutated/FLT3-ITD negative cases showing the better prognosis. Lack of MLD impact on survival was confirmed by multivariate analysis that highlighted FLT3-ITD as the most significant prognostic parameter in NPM1-mutated AML. Our findings indicate that NPM1 mutations rather than MLD dictate the distinctive features of NPM1-mutated AML. Thus, irrespective of MLD, NPM1-mutated AML should be considered as one disease entity clearly distinct from AML with MD-related changes. These findings have important diagnostic and prognostic implications in AML. All bone marrow samples were obtained from untreated patients at the time of diagnosis. Cells used for microarray analysis were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. 48 samples

2010-07-30 | E-GEOD-18018 | biostudies-arrayexpress

Multilineage dysplasia and AML with mutated nucleophosmin

2010-07-01 | GSE18018 | GEO

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

Project description: Not available

| S-EPMC3736571 | biostudies-literature

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Project description: Not available

| S-EPMC12060156 | biostudies-literature

Guideline-based indicators for adult patients with myelodysplastic syndromes.

Project description: Not available

| S-EPMC7448599 | biostudies-literature